KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Eli Lilly (LLY) over the last 14 years, with Q4 2025 value amounting to $897.3 million.

  • Eli Lilly's Shares Outstanding (Weighted Average) fell 36.64% to $897.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $897.3 million, marking a year-over-year decrease of 36.64%. This contributed to the annual value of $897.3 million for FY2025, which is 36.64% down from last year.
  • According to the latest figures from Q4 2025, Eli Lilly's Shares Outstanding (Weighted Average) is $897.3 million, which was down 36.64% from $897.8 million recorded in Q3 2025.
  • Eli Lilly's Shares Outstanding (Weighted Average)'s 5-year high stood at $908.8 million during Q1 2021, with a 5-year trough of $897.3 million in Q4 2025.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $901.0 million (2023), whereas its average is $901.9 million.
  • In the last 5 years, Eli Lilly's Shares Outstanding (Weighted Average) plummeted by 68.27% in 2022 and then rose by 8.89% in 2024.
  • Eli Lilly's Shares Outstanding (Weighted Average) (Quarter) stood at $907.0 million in 2021, then fell by 0.58% to $901.7 million in 2022, then fell by 0.17% to $900.2 million in 2023, then grew by 0.04% to $900.6 million in 2024, then fell by 0.37% to $897.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $897.3 million for Q4 2025, versus $897.8 million for Q3 2025 and $898.3 million for Q2 2025.